Preliminary study of the safety and efficacy of donepezil hydrochloride in children with down syndrome: A clinical report series

American Journal of Medical Genetics, Part A

Volumn 143, Issue 13, 2007, Pages 1408-1413

  Spiridigliozzi, Gail A ^a   Heller, James H ^a   Crissman, Blythe G ^a   Sullivan Saarela, Jennifer A ^a   Eells, Rebecca ^a   Dawson, Deborah ^b   Li, Jennifer ^a   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Attention; Cholinesterase inhibitors; Cognitive function; Donepezil hydrochloride; Down syndrome; Efficacy; Memory; Safety

Indexed keywords

DONEPEZIL;

ADOLESCENT; AGGRESSION; ANOREXIA; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IRRITABILITY; LOOSE FECES; MALE; MEMORY; MOOD; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; URINE INCONTINENCE; VOMITING;

ADOLESCENT; CHILD; CHOLINESTERASE INHIBITORS; COGNITION; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; MALE; PIPERIDINES; TREATMENT OUTCOME;

EID: 34447314736     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31790     Document Type: Article

References (23)

1. Berger-Sweeney J. 2003. The cholinergic basal forebrain system during development and its influence on cognitive processes: Important questions and potential answers. Neurosci Biobehav Rev 27:401-411.
2. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. 1999. The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dement Geriatr Cogn Disord 10:237-244.
3. Conners CK. 1997. Conners' rating scales-revised, technical manual. North Tonawanda, NY: Multi-Health Systems Inc.
4. Florez J, del Arco C, Gonzalez A, Pascual J, Pazos A. 1990. Autoradiographic studies of neurotransmitter receptors in the brain of newborn infants with Down syndrome. Am J Med Genet Suppl 7:301-305.
5. Galdzicki Z, Siarey RJ. 2003. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav 2:167-178.
6. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS. 2006a. Clinical trials in children with Down syndrome: Issues from a cognitive research perspective. Am J Med Genet Part C Semin Med Genet 142C:187-195.
7. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells R, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS. 2006b. Safety and efficacy of rivastigmine in adolescents with Down syndrome: A preliminary 20-week open-label study. J Child Adolesc Psychopharmacol 16:755-765.
8. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS. 2004. Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. Am J Med Genet Part A 130A:325-326.
9. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. 2003. Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. Am J Med Genet Part A 116A:111-116.
10. Kish SJ, Distefano LM, Dozic S, Robitaille Y, Rajput A, Deck JH, Hornykiewicz O. 1990. [3H]vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 117:347-352.
11. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. 1999. Cholinergic therapy for Down's syndrome. Lancet 353:1064-1065.
12. Kiss J, Schlumpf M, Balazs R. 1989. Selective retardation of the development of the basal forebrain cholinergic and pontine catecholaminergic nuclei in the brain of trisomy 16 mouse, an animal model of Down's syndrome. Brain Res Dev Brain Res 50:251-264.
13. Korkman M, Kirk U, Kemp S. 1998. NEPSY: A developmental neuropsychological assessment. San Antonio: The Psychological Corporation.
14. Lott IT, Osann K, Doran E, Nelson L. 2002. Down syndrome and Alzheimer disease: Response to donepezil. Arch Neurol 59:1133-1136.
15. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. 2001. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57:481-488.
16. Prasher VP, Adams C, Holder R. 2003. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: Open label study. Int J Geriatr Psychiatry 18:549-551.
17. Prasher VP, Huxley A, Haque MS. 2002. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot study. Int J Geriatr Psychiatry 17:270-278.
18. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. 1995. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177-184.
19. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, Mobley WC. 2006. Increased App Expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29-42.
20. Semel E, Wiig E, Secord W. 1995. Clinical evaluation of language fundamentals-3. San Antonio: The Psychological Corporation.
21. Sparrow SS, Balla DA, Cicchetti DV. 1984. Vineland adaptive behavior scales - Interview edition. Circle Pines: American Guidance Service.
22. Yates CM, Simpson J, Gordon A. 1986. Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci Lett 65:189-192.
23. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A. 1983. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280:119-126.